Key result
Targeted therapies directed at specific molecular targets offer promising treatment options for metastatic bone sarcomas, highlighting a strong need for continued Phase II and III clinical trials.
Targeted therapies represent a promising future direction for the treatment of advanced, chemotherapy-resistant bone sarcomas, though further clinical trials are required.
Should not yet change practice for metastatic bone sarcomas; extends rationale for targeted therapy trials.
INTRODUCTION: Bone sarcomas are rare malignancies and once advanced, there is limited response to current chemotherapeutic regimens. Targeted therapies could have substantial impact on these diseases. AREAS COVERED: Specific molecular targets of bone sarcomas are reviewed along with the various targeted therapies that have potential to change the outcome of these chemotherapy resistant diseases. EXPERT OPINION: There are promising pathways identified that targeted inhibitors could provide better treatment options for metastatic bone sarcomas. There is a strong need for continued Phase II and III clinical trials investigating these molecularly targeted therapies.
No takes yet. Share an insight, caveat, or question.
Yarber et al. (2011) conducted a review in Bone sarcomas. Targeted therapies was evaluated. Targeted therapies directed at specific molecular targets offer promising treatment options for metastatic bone sarcomas, highlighting a strong need for continued Phase II and III clinical trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: